The Safety and Immunogenicity of an Interleukin-12–Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection-Reference-Cited by-同舟云学术

The Safety and Immunogenicity of an Interleukin-12–Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection

Published:2016-02-01 Issue:2 Volume:71 Page:163-171
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Jacobson Jeffrey M.,Zheng Lu,Wilson Cara C.,Tebas Pablo,Matining Roy M.,Egan Michael A.,Eldridge John,Landay Alan L.,Clifford David B.,Luetkemeyer Anne F.,Tiu Jennifer,Martinez Ana L.,Janik Jennifer,Spitz Teresa A.,Hural John,McElrath Juliana,Frahm Nicole

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference31 articles.

1. Emerging strategies to deplete the HIV reservoir.;Archin;Curr Opin Infect Dis,2014

2. . Stimulation of HIV-1 specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.;Shan;Immunity,2012

3. Treatment interruption as a tool to measure changes in immunologic response to HIV-1.;Kutzler;Curr Opin HIV AIDS,2008

4. . Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T cell responses.;Koup;PLoS One,2010

5. . Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.;Goepfert;J Infect Dis,2011

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced micro/nano-electroporation for gene therapy: recent advances and future outlook;Nanoscale;2024

2. Generating and measuring effective vaccine-elicited HIV-specific CD8+ T cell responses;Current Opinion in HIV and AIDS;2023-09-20

3. Vaccine Adjuvants: Selection Criteria, Mechanism of Action Associated with Immune Responses and Future Directions;IRAN J IMMUNOL;2023

4. Safety and durability of AGT103-T autologous T cell therapy for HIV infection in a Phase 1 trial;Frontiers in Medicine;2022-11-14

5. New vector and vaccine platforms: mRNA, DNA, viral vectors;Current Opinion in HIV and AIDS;2022-11